Recently, the stock price movement of Bristol-Myers Squibb (BMY) has not reflected market confidence in its future growth. However, several financial indicators are sending distinctly different signals.
Data shows that the pharmaceutical maker has a forward price-to-earnings ratio of about 10 times, the lowest among its 11 peers in the S&P 500. The stock’s modest 8% gain so far this year has pushed its dividend yield above 4%, making it the second-highest among comparable pharmaceutical companies, trailing only Pfizer (PFE). More notably, based on its price-to-free-cash-flow ratio of 9.9 times over the past 12 months, Bristol-Myers Squibb ranks as the third cheapest among the 59 healthcare stocks in the S&P 500. For a company expected to generate approximately $46 billion to $47.5 billion in revenue this year, this valuation level is exceptionally low.
Of course, what truly concerns the market is not the numbers themselves, but the issue of patent expirations. Several blockbuster drugs, including Revlimid and, in the future, Eliquis, are set to face increasing generic competition in the coming years. This has likely led investors to view Bristol-Myers Squibb as a company poised for long-term revenue decline.
However, the latest earnings results show that the company’s new products have begun to offset these losses—or market fears of losses. In the first quarter of 2026, Bristol-Myers Squibb reported revenue of $11.5 billion, a 3% year-over-year increase. Its portfolio of growth products saw revenue rise 12% to $6.2 billion, now accounting for more than half of the company’s total revenue. Several new drugs are growing rapidly, with Breyanzi revenue surging 56% year-over-year, Camzyos jumping 97%, and Reblozyl increasing 16%. Meanwhile, Eliquis, the blockbuster blood thinner developed in collaboration with Pfizer, remains solid, generating $4.14 billion in the first quarter alone, a 16% year-over-year increase. Bristol-Myers Squibb recently projected that despite pricing pressures related to Medicare negotiations, Eliquis’s revenue could still grow another 10% to 15% in 2026.
On cost control, the company is becoming more aggressive. Management has stated that restructuring initiatives and productivity enhancement programs are expected to generate approximately $2 billion in annual cost savings by 2027.
Furthermore, Bristol-Myers Squibb still boasts one of the deepest R&D pipelines among large pharmaceutical companies. The company currently has multiple late-stage oncology, immunology, and cardiovascular programs advancing through key trials. Management has highlighted several regulatory and clinical catalysts expected in 2026.
Of course, this is not a “risk-free” pharmaceutical stock. The patent cliff is real. Revlimid revenue continues to decline due to generic competition, and Eliquis will face significant exclusivity pressures after the end of this decade. But current valuations—particularly based on price-to-free-cash-flow—already largely reflect these pessimistic expectations, even though the company’s free cash flow itself is not particularly unfavorable.
In summary: A company with annual revenue projected at $46 billion to $47.5 billion, a dividend yield above 4%, and a rapidly growing portfolio of new drugs would not typically trade at a forward P/E or free-cash-flow multiple of around 10 times unless the market is being overly short-sighted. Currently, Bristol-Myers Squibb appears priced for stalled growth. But if management continues to expand the new product portfolio and stabilize the decline of older products, today’s valuation may eventually look far too cheap.
